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Abstract
Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the
disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle
conditions which have more chronic and indolent course. These include an increased deployment of safe screening
methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of
increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising
radiation-free method, which can support a significant number of clinically relevant measurements and offers new
opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical
Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed
translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The
objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the
accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and
weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the
existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for
widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in
clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid
development, regular updates of the present recommendations are foreseen.
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1. Rationale
Cardiovascular disease (CVD) remains the greatest cause
of morbidity and mortality globally. The changing nat-
ural history of CVD due to improved care of acute con-
ditions and ageing population necessitates new strategies
to tackle conditions with a more chronic and indolent
course. These include an increased deployment of safe
screening methods, life-long surveillance, and monitoring of
both disease activity and tailored-treatment, by way of in-
creasingly personalised medical care. Cardiovascular mag-
netic resonance (CMR), is a non-invasive, radiation-free
method, which can support a significant number of clinically
relevant measurements, offers many new opportunities to
advance the state of art of diagnosis, prognosis and treatment
of patients with CVD. Several key CMR measurements are
highly accurate and reproducible, providing gold-standard
measures in cardiovascular imaging. Published agree-
ments on standardized acquisition and post-processing
ensure robustness and transferability for widespread use
[1, 2]. With the growing evidence on diagnostic and
prognostic role, CMR measurements may be well-suited
as imaging biomarkers for assessment of novel clinical
management pathways and therapies. Yet, despite the
enthusiasm, the body of evidence, and the overt potential
to improve patients care, the impact of CMR towards
clinical cardiology practice remains limited, by way of
access to the technology (scanner, scan-time), oper-
ational imaging skill and allocation of the healthcare
resources. Hence, the objective of this taskforce is to
emphasize the evidence where CMR-guided clinical care
indeed means that deployment of resources results in
meaningful and efficient use, by providing an appraisal of
evidence on analytical validation, including the accuracy
and precision, and qualification of parameters in disease
context (part I). The manuscript structure, preparation
and evidence appraisal procedures were based on a prior
agreement within the SCMR CT Writing Group (WG)
(Fig. 1- Flowchart), as well as general guidance of the
SCMR on Expert Consensus publications. This included
the assignment of themed subsection to a minimum of 2
and a maximum of 5 authors with background of contri-
bution to the field, which are included in the authors’ list
(Table 1). The resulting material was subsequently
reviewed and edited to adopt a common reporting format
of a summary-text and evidence-rich tables. As per SCMR
CT WG consensus, the studies were included, if providing
a robust independent (non-CMR) comparator (validation)
or including > 50 subjects (normal values) or > 25 in pa-
tient group (proof of concept), and > 100 for outcome
study. Smaller studies were included if no other evidence
was available and with consensus of the writing group.
We strived to set out qualified recommendations for ap-
propriate surrogate use of imaging measures biomarkers
using consensus statements produced by the SCMR CT
WG upon the presentation of summarised data. The
weighing of evidence was based on consensus criteria of
the SCMR CT WG, and assigned as promising, if multiple
(3 or more) publications from independent groups existed,
and favourable, if also cited by the practice guidelines. The
final steps included a review and approval by all
co-authors, followed by 3 independent external reviewers,
commissioned by the SCMR Board of Trustees, in line
with the societal rules on consensus statements. This re-
port clarifies the strengths and weaknesses of the state of
art, as well as the gaps in the current evidence (Table 2).
The SCMR CT WG statements are based on the available
evidence up to and including April 2017. The target
audience includes clinical investigators considering
the application of CMR-imaging endpoints in clinical
studies and trials involving human subjects. Themed
imaging-endpoint guidance on trial design to support
drug-discovery or change in clinical practice (part II),
will be presented in a follow-up paper in due course. As
CMR continues to undergo rapid development, regular
updates of the present recommendations are foreseen.
2. Imaging parameters as biomarkers and endpoints
A biomarker is a characteristic that can be objectively
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes or pharmaco-
logical response to a therapeutic intervention [3]. They
Puntmann et al. Journal of Cardiovascular Magnetic Resonance  (2018) 20:67 Page 2 of 23
can serve as indicators of a disease presence or activity
and reflect the rate of disease progression and response to
treatment. Reliable biomarker’s characteristics include an
accurate measurement, which is reproducible across mul-
tiple laboratories, and in a clinical setting, an adequate
sensitivity and specificity for disease detection, severity
and prognostic outcome. The biomarker evaluation
framework foresees the following steps of biomarker char-
acterisation: analytical validation, clinical qualification and
utilization, and subsequently, a constant re-evaluation of
the preceding steps [3]. It is also a sequence of inter-
dependent steps, which continually inform each other.
This process clarifies the biomarker’s application within a
defined disease context and possible roles, from explora-
tory use to surrogate endpoint. Analytical validation in-
volves assessment of assays or techniques supporting the
acquisition of measurements, as well as establishing the
range of conditions, under which the measurement will
give reproducible and accurate data. Important perform-
ance metrics include precision, accuracy, lab-to-lab repro-
ducibility, limits of detection and signal-to-noise, as well
as determination of the reference values. Qualification
refers to summation of the available evidence about the
biomarker-disease-relationship, including its relevance,
diagnostic and prognostic value. Also, causal relationships
Fig. 1 The illustration of reviewing steps involved in generation of this position paper. The manuscript structure, preparation and evidence
appraisal procedures were based on a prior agreement within the SCMR Clinical Trial (CT) Writing Group (WG), as well as general guidance of the
SCMR on Expert Consensus publications. Please see the Rationale for details
Table 1 Characteristics of contributing authors
Contributing authors’ characteristics Count (%); Median(IQR)
MR Vendors
Siemens 26 (53)
Philips 17(35)
General Electrics 6(12)
Field Strength
1.5 Tesla 37(76)
3.0 Tesla 17(35)
Both 15(31)
Specialty
Cardiology 25(51)
Radiology 18(38)
Other 5(10)
Number of previously co-authored
Societal consensus papers (any)
3(1–4.5)
Number of previously co-authored
SCMR Consensus papers
2(1–3)
aNumber of previously co-authored
papers in the CMR field
86(57–141)
bNumber of previously co-authored
papers in the author’s themed field
44(23–68)
Search criteria (Pubmed): aSurname, First initial + cardiac + magnetic;
bSurname, First initial + magnetic+ theme
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to disease pathogenesis are considered, including the ef-
fects of therapeutic intervention on the imaging marker
and to the clinical endpoints of interest. (4) Utilization is
a contextual analysis of the above evidence with regards to
the definition of the context for the biomarker’ proposed
clinical use. In addition, factors such as prevalence, het-
erogeneity, morbidity and mortality of the disease, as well
as the risks and benefits of an intervention are considered.
3. Executive statements - SCMR Clinical Trial
Writing Group
CMR uniquely provides quantitative information on car-
diac function (LV, RV and valves) and myocardial tissue
characteristics that are diagnostic of acute and chronic
disease. CMR involves contrast- and non-contrast media
imaging techniques. CMR does not involve ionising radi-
ation and can be safely repeated.
Ventricular volumes and function
The ability of CMR to assess left ventricular (LV) and right
ventricular (RV) volumes and function accurately and pre-
cisely has been demonstrated in excellent validation studies
with a large body of evidence on inter-study reproducibility.
Standardised approach to quantification is available. There
are extensive sets of normal values for gradient echo (GRE)
sequences, whereas smaller sets support the modern acqui-
sition techniques (balanced steady state free precession
(bSSFP)). Thus, the appropriate reference ranges need to be
selected for the technique used. The accuracy and reprodu-
cibility of novel post-processing algorithms based on signal
intensity thresholding remains unknown. CMR is rightly
regarded as the reference standard for the assessment of left
and right ventricular volumes and left ventricular mass.
CMR should be considered as the first line technique in
clinical trials requiring one of these parameters for in- or
exclusion or as an endpoint. The evidence for the use of
quantification of cardiac function and volumes is
favourable.
i. Regional wall motion, deformation and dyssynchrony
CMR tagging techniques have been well validated. Other
CMR based strain imaging techniques have been either
directly compared with tagging or indirectly against a
technique originally compared to tagging. Accuracy, preci-
sion and normal values are still to be further improved es-
pecially for radial strain and strain velocities. While
normal values are available they show considerable re-
gional variation as well as variation between different
studies. There is very limited data on inter-study reprodu-
cibility. CMR-based strain-imaging techniques seem simi-
larly suited as echocardiographic techniques for assessing
longitudinal motion and strain. The evidence for the use
of CMR-based strain imaging techniques is promising.
Diastolic function
CMR has been reasonably well validated versus pressure
volume (PV) loops and echocardiography for diastolic
filling, atrial volumes and function and transmitral and
pulmonary venous flow. More work is required to
fully establish its role based on classic LV inflow (fill-
ing) parameters (e.g. E/e’). Although CMR may have
advantages over other techniques by direct assessment
of myocardial tissue, more evidence to support the
use of CMR-based assessment of diastolic function is
needed.
Late gadolinium enhancement (LGE)
Late gadolinium enhancement (LGE) has been exten-
sively validated as a marker of irreversible damage post
myocardial infarction in animals as well as versus biop-
sies and in explanted hearts, demonstrating excellent ac-
curacy and precision superior to alternative techniques.
There are strong data on inter-study reproducibility.
LGE is a strong parameter to predict outcome and has
been shown to be superior to volumes and function.
CMR based LGE should be used as the first line tech-
nique in clinical trials requiring the assessment of re-
gional scar or fibrosis for inclusion or exclusion or as an
endpoint. CMR should also be employed for optimal
risk-classification of trial subjects with ischemic or
non-ischemic cardiomyopathies. The evidence for the
use of LGE imaging for visual detection of regional myo-
cardial fibrosis and quantification of ischaemic scar is
favourable. The quantification of non-ischaemic scar re-
mains promising.
T2-weighted imaging
T2-weighted imaging (T2W) has been well validated in
animals, phantoms and humans and demonstrates an ex-
cellent ability to visualize areas of significantly increased
tissue water or myocardial haemorrhage. There are scarce
data on inter-study reproducibility in acute myocardial in-
farction. There is a small number of outcome studies in
area at risk (AAR), including an application in a clinical
trial. There is lack of reproducibility data and outcome
studies for T2W-oedema imaging (or Lake-Louise criteria)
in inflammatory cardiac conditions. Due to the availability
of many different sequences no generally accepted stand-
ard has been defined. For clinical trials, it is important to
use a validated and standardized approach amongst differ-
ent centres and vendors and use normal values and effect
sizes specifically for these sequences. Timing of imaging
after an acute event must be highly standardized.
Contrast-enhanced cine bSSFP imaging is emerging as
possible time-efficient option for imaging the AAR. The
evidence for the use of T2W imaging of AAR is
promising.
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T1-mapping
Myocardial T1-mapping has been well validated in
phantoms, animal models, and human biopsies and
explanted hearts. In model diseases, the various acquisi-
tion techniques demonstrate the ability to relate to dif-
fuse fibrosis, increased extracellular space and oedema,
in a quantifiable fashion. T1-mapping indices have been
shown to be strong predictors of outcome in
non-ischaemic dilated cardiomyopathies, superior to vol-
umes, function and LGE. Due to the availability of many
different sequences, no generally accepted standard has
been defined. To employ T1 mapping in clinical trials,
the use of validated (well understood sequence) and
standardized approach amongst different centres and
vendors is mandatory, due to the different normal values
and effect sizes between various sequences. CMR
T1-mapping may be considered as a standard for ad-
equate risk-assessment of patients with non-ischemic di-
lated cardiomyopathy in clinical trials. The evidence for
the use of T1 mapping is promising.
T2-mapping
Myocardial T2-mapping has been well-validated in
phantoms, animal models, and human biopsies. The
various techniques demonstrate an excellent ability to
relate to myocardial water content/oedema, in a quanti-
fiable fashion. Due to the availability of many different
sequences no generally accepted standard has been de-
fined. Similar to T1 mapping above, the use a validated
and standardized approaches amongst different centres
and vendors is mandatory for the use in clinical trials,
due to the different normal values and effect sizes specif-
ically for these sequences. The timing of imaging after
an acute event must be highly standardized. The evi-
dence for the use of T2 mapping is promising.
T2* -mapping
Myocardial T2* mapping measurements in thalassemia
have been excellently validated and standardized for
1.5 T and provide superior outcome data if used for
therapy guidance. As such T2* can be regarded as the
clinical reference standard in thalassemia. T2* measure-
ments during or shortly after an acute coronary or vas-
cular event provides important prognostic information
in terms of short-term LV remodelling. The evidence for
the use of T2* mapping is favourable.
Perfusion imaging
CMR perfusion imaging has been well-validated against
animal models, alternative techniques as well as related to
outcomes. In various meta-analyses, CMR perfusion im-
aging has been confirmed as the most accurate technique
for non-invasive assessment of myocardial ischemia. How-
ever, due to the availability of many different sequences
and post-processing parameters, no generally accepted
standard for (semi-) quantification has been defined.
While there is good correlation of quantification tech-
niques with microspheres and positron emission tomog-
raphy (PET), normal values are variable and show high
inter-study variability. Perfusion imaging should be con-
sidered as a first line technique for assessing the presence,
extent and localization of inducible ischemia, its use for
full quantification requires locally validated and standard-
ized sequences with specific normal values. Trials asses-
sing reduction in ischaemic burden following intervention
are currently lacking. The evidence for the use of myocar-
dial perfusion imaging for visual detection of ischaemia is
favourable. Quantitative perfusion imaging is increasingly
becoming available. At this stage the various approaches
require more validation, especially as large outcome stud-
ies have been performed with visual analysis.
Vascular imaging
Vascular imaging provides robust quantifiable data on
vessel diameters, vessel wall thickness and vessel disten-
sibility. Vascular stiffness measurements aside, there are
limited data on truth validation or interstudy reproduci-
bility for some vascular areas. Limited data supports
CMR being non-inferior to computed tomography (CT)
for aortic visualization and dimensions. Large databases
of normal data are available. CMR vascular imaging is
well suited to assess vascular anatomy and function.
Aortic and carotid vessel wall imaging, are robust
markers of atherosclerotic burden in these vessels and
can be used in clinical trials. Coronary vessel wall im-
aging and tissue characterization is a promising research
tool but require further advances in the robustness and
simplicity of the methods.
4. Ventricular volumes and mass
i. Global volumes, thickness and function
Quantification of cardiac volumes at end-diastole and
end-systole, LV mass and global systolic function repre-
sent the measurements of cardiac imaging, which are fun-
damental to decision making in clinical cardiology. These
are obtained using standard cine images by CMR and can
be processed by virtually every available post-processing
software. Cine imaging also supports assessment of re-
gional wall motion abnormalities, either visually or by
strain quantification (presently limited to research).
Acquisition
 Cine imaging (bSSFP sequences)
 Acquisition defined in SCMR Standardized
Protocols [1]:
○ complete LV and RV coverage using short axis
(SAX) stack of slices
○ long axis LV views.
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 Older approaches of cine imaging based on fast
gradient recalled echo (GRE) sequences: compared
to bSSFP sequences, GRE sequences lead to larger
LV mass and smaller LV volumes.
Post-processing
 Standardised approach defined in SCMR
Standardized Post-processing recommendations [2]
○ LV mass measurement: inclusion of papillary
muscles into LV cavity reduces accuracy
compared to autopsy, but results in higher
precision (smaller observer variability);
○ LV dimensions and wall thickness: most
reproducible in 3-chamber view [4];
○ An early study showed higher reproducibility of
RV volumes; measured in a transverse (TRA)
stack [5], a later study reaffirmed that both SAX
and TRA are similarly reproducible, as long as
both ventricles acquired in entirety [6, 7].
○ TRA stack does not support reproducible RV
mass measurements [2, 7]. No data available for
SAX stack.
○ The accuracy and reproducibility of novel post-
processing algorithms based on signal intensity
thresholding is unknown
Validation
 LV mass: excellent validation against gold-standard
in animals and excised human hearts after trans-
plantation (Additional file 1: Table 3ai.1).
 LV function/cardiac output: limited validation
against invasive conductance catheters [8, 9]
Precision
 A large body of evidence exists on interstudy, inter-
and intraobserver reproducibility (Additional file 1:
Table 3ai.2)
 A body of evidence supports superior precision of
CMR-derived measurements compared to:
○ radionuclide ventriculography [10]
○ nuclear medicine techniques (PET, single photon
emission computed tomography (SPECT)) [11]
○ transthoracic 2- and 3D echocardiography [12, 13]
○ cardiac CT [14]
 Benchmarking datasets available [15]
Normal values
 Normal values available have been derived for various
field strengths, imaging sequences, post-processing ap-
proaches, age-, sex- and ethnicity groups (Additional
file 1: Table 3ai.3), summarised in [16].
 There is moderate variability in normal ranges
depending on the population studied and method of
quantification.
 SCMR CT WG members recommend the use of
normal values that correspond the mode of acquisition
and postprocessing (as per SCMR recommendations
for acquisition and postprocessing (1,2).
Qualification and utilisation
 Diagnostic interpretation and clinical decision
making underlying practice guidelines is based on
evidence derived with echocardiography. The cut-off
values (most notably for LV ejection fraction) have
been adopted by other imaging modalities, including
CMR. The original evidence base by transthoracic
echocardiography has been revalidated and
expanded upon by CMR (Additional file 1:
Table 3ai.4).
 Abnormal changes in cardiac volumes, function and
LV mass indicate the presence of disease and relate
to worse outcome. LV volumes and function by
echocardiography have been described as the
strongest predictor of survival in heart failure (HF)
[17–20]. Recent data with CMR LGE
(Additional file 2: Table 3b-i.4) and T1-mapping
indices (Additional file 3: Table 3c-i.6) show
consistently better prognostic predictive value in HF
and non-ischemic cardiomyopathy (NICM).
ii. Regional wall motion and deformation
Myocardial strain imaging enables time-resolved quanti-
fication of myocardial contraction and relaxation, which
is less influenced by the ventricular pressure/volume
loading conditions. Characterisation of these events in
various conditions, with aim to better understanding of
tissue architecture and the underlying efficiency of de-
formation, remains an active research domain. Once a
complex and often time-consuming acquisition and
post-processing, strain imaging with CMR is now made
possible using standard cine imaging. Owing to the is-
sues with the reproducibility and an overall lack of in-
cremental diagnostic and prognostic data, the value of
strain imaging in clinical use remains investigational.
Acquisition
○ Cine imaging (feature tracking)
○ Tagging (spatial modulation of magnetization-
SPAMM, complementary –SPAMM (CSPAMM)
[21], harmonic phase image analysis [22])
○ Displacement ENcoding with Stimulated Echoes
(DENSE) [23]
○ Strain encoding imaging (SENC) [24]
Post-processing
○ Visual segmental analysis [2]
○ Regional wall motion score
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○ Deformation/strain analysis (tagging,
feature tracking [25])
○ Dyssynchrony [26]
Results may be presented either segmental (provided
for 17 segments as per AHA/ACC) or global
(deformation components: longitudinal, radial,
circumferential, torsion) values.
Validation
 Validation in phantoms and animals
○ Tagging is referred to as the reference standard
for strain imaging [27] [28, 29](Additional file 1:
Table 3ii.1)
○ DENSE [30]
 Comparative studies to tagging:
○ DENSE can provide greater reliability and
resolution of segmental analysis [30]
○ Feature tracking [25]
 Comparative studies to echocardiography:
○ Strain by DENSE, tagging, feature tracking
(reviewed in [31, 32])
○ Dyssynchrony by feature tracking [33]
Precision
 Wall motion based on visual assessment of each
segment, observer dependent on training and
experience [34] (Additional file 1: Table 3ii.2.)
 Reproducibility may be improved with automated
processing [27]
 Some studies demonstrated superior precision of
tagging [35], however, the endocardial border may
be obscured by a tag line prohibiting adequate
assessment of wall thickening
 The best spatial resolution for strain imaging is
currently given by DENSE [36]. Fast processing
methods are available for analysis of strain and
displacement [37].
 Feature-tracking reproducibility remains
problematic, especially for radial strain [38, 39].
○ Circumferential strain preforms best, if averaged
over the whole slice. Regional estimates are
more variable (reviewed in).
○ Considerable inter-vendor variability of outputs
[39, 40]
 Benchmarking datasets available [41].
Normal values
 Normal values available for global strain
components (Additional file 1: Table 3ii.3).
 Several studies available for segmental values [42–44],
of note, regional values vary significantly in a given
heart complicating the definition of normal values and
cut-offs.
 One study reported normal values for strain
according to segment, age, sex and ethnicity [27]
Qualification/utilisation
Strain imaging with CMR remains an exploratory research
domain, due to complex and often time-consuming
post-processing. Outcome data suggest utility in addition
to standard measures of care in clinical management.
(Additional file 1: Table 3ii.5)
1. Regional wall motion score is used as a single value
to describe wall motion abnormalities or changes
during stress testing [45];
2. Outcome data for deformation analysis of high dose
dobutamine stress testing with SENC [46];
3. Global longitudinal strain is a better predictor of
outcome in DCM than volumes or ejection fraction [47];
4. Intervendor variability of outputs for feature
tracking implies that various algorithms may not
convey equivalent information.
Development directions
1. Standardisation of acquisition and post-processing
approaches
2. Development of robust normal values for vendor-
specific acquisition/post-processing
3. Establishment of characteristic disease-specific or
pathophysiology specific signatures of deformation
abnormalities (diagnostic and prognostic relevance)
4. Determination of reversibility of parameters/
signatures with treatment
5. Utility in guiding treatment through clinical trials.
iii. Diastolic function
Assessment of diastolic relaxation is an indirect approach
to myocardial tissue characterisation and can be done by
CMR by employing analogous approaches to those used
in echocardiography. Increased myocardial stiffness com-
monly coincides with the states of increased LV wall thick-
ness, either due to global pathological myocardial
processes, such as accumulation of myocardial fibrosis or
amyloid, or due to regional myocardial injury, such as is-
chaemic scar. Because CMR provides means of direct tis-
sue characterisation, by LGE and T1 mapping, assessment
of diastolic function by CMR is not commonly used.
Acquisition
 Time resolved curve of left ventricular diastolic
filling from cine SAX stack [48, 49]. As in
echocardiography, these parameters are dependent
on loading conditions.
 2- and 4-chamber cine views for measurement of left
atrial (LA) volume
 Phase-contrast gradient echo sequence acquisitions:
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○ Through-plane flow measurement across mitral
valve, pulmonary venous inflow (velocity
encoding 130 cm/sec)
○ Basal SAX slice measurement of mitral flow and
annulus velocities (velocity encoding < 30 cm/sec)
 Tagging [50]
Post-processing
 Transmitral E and A waves
 Pulmonary venous inflow S, D and A waves
 Mitral annulus velocity e’
 LA size
 Peak early diastolic strain rate (PEDSR)
Validation
 Against PV loops [51]
 Comparative studies with echo [52–54]
Normal values
 Normal values available for early diastolic velocities
Development directions
1. Standardisation of acquisition and post-processing
approaches
2. Development of robust normal values for vendor-
specific acquisition/post-processing
3. Establishment of characteristic disease-specific
or pathophysiology specific signatures of
diastolic abnormalities (diagnostic and
prognostic relevance)
4. Determination of reversibility of parameters/
signatures with treatment
5. Utility in guiding treatment through clinical trials.
5. Tissue characterisation
i. Late gadolinium enhancement
LGE is a myocardial tissue characterization technique,
which demonstrates regional myocardial tissue differences
based on differential uptake/washout of gadolinium-based
contrast agent (GBCA). LGE is optimally suited to
visualize myocardial infarction and scar, as well as areas of
regional scar/fibrosis in non-ischaemic cardiomyopathies,
such as in hypertrophic and dilated cardiomyopathy,
sarcoidosis or myocarditis. In acute myocardial infarction
or myocarditis, LGE co-localises with areas of cell-necrosis
or oedema. Conversely, LGE can also reveal unenhanced
areas in the core of the contrast-enhanced regions,
representing either microvascular obstruction (MVO)
(a no-(re)flow phenomenon) or intramyocardial haem-
orrhage (IMH).
Acquisition
 Inversion recovery (IR) prepared T1 weighted
gradient echo sequences with either individually
adapted prepulse delay (‘to achieve myocardial
signal nulling’) and/or inline Phase-Sensitive
Inversion-Recovery (PSIR)-based reconstruction
algorithm [1]
 Acquired as in full LV coverage in short axis and
long axis views during mid-diastole
 ~ 10 min delay time from administration of GBCA [1]
 GBCAs lead to:
○ shortening of T1 - > increased signal intensity in
areas of intense GBCA accumulation compared
to areas with quick wash-out, such as normal
myocardium;
○ differential distribution between myocardial
regions with intact myocardial cells
(membranes) and expanded extracellular space
due to necrosis, fibrosis or scar;
○ in amyloidosis, there is commonly poor contrast
difference between the blood and myocardium
due to expansion of the extracellular volume
throughout the myocardium, resulting in lower
gradient in GBCA concentration between these
two tissues, save for the bright endocardial
border;
 Evidence of LGE is a marker of expanded
extracellular space, most commonly seen due to
necrotic myocardium or scar tissue
 Methods to assess microvascular obstruction (MVO)
(and IMH) include [55–57]:
○ first pass perfusion imaging,
○ early IR-TFE imaging (app. 1 min, no ‘nulling’,
long prepulse delay > 400 msec)
○ LGE (app. 10–20 min)
○ native T1
○ Contrast-enhanced cine-bSSFP
○ First pass and early hypoenhancement less
strongly related to remodelling and clinical
outcomes than LGE
 Alternative ways to IMH imaging by T2*
(see section Mapping) [58].
Post-processing
 Visual assessment reporting on the presence,
type (ischemic/non-ischemic), location, and
transmurality [2]
 Quantitative assessment (i.e. LGE extent) can be
based on several approaches:
○ Manual approach (i.e. visual delineation)
○ full width half maximum (FHWM)
○ The “n”-SD approach (standard deviations, SD):
2SD (for nonischaemic scar)/5SD of the noise
(for infarction) above the signal intensity of
normal myocardium [2].
○ LGE extent is reported as % of LV mass
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 MVO can be measured manually or by SD-
thresholds. The strong contrast between scar and
MVO results in a highly reproducible delineation [59].
Validation
 Excellent validation of LGE imaging for the
presence, extent and transmurality of LGE against
reference standard for ischemic scar and non-
ischemic fibrosis (animal experiments, human
endomyocardial biopsies (EMB), explanted hearts)
(Additional file 2: Tables 3b-i.1 and 3b-i.2)
○ In acute myocardial infarction, LGE
overestimates infarct size (see T2 imaging
section) reviewed in [60].
○ CMR favourably compares to alternative
techniques (SPECT, PET) due to its higher
sensitivity and spatial resolution to resolve
infarct transmurality (based on better spatial
resolution) (Additional file 2: Table 3b-i.3)
Precision
 Large body of evidence on interstudy, inter- and
intraobserver variability in acute and chronic
ischemic scar as well as in NICMs (Additional file 2:
Table 3b-i.2)
 No comparison of precision to SPECT/PET due to
the poor interstudy reproducibility of the later
methods
 No benchmarking datasets available
Normal values
 Normal reference defined as absence of LGE
 Interpretation by pattern (ischemic, non-ischemic,
patchy, diffuse), localization (typical coronary artery
territory, mid-wall, epicardial, septal, lateral), trans-
murality (% of wall thickness).
Qualification and utilisation (Additional file 2:
Table 3b-i.4)
 Excellent diagnostic tool for the determination of
chronic myocardial infarction and regional fibrosis
in cardiomyopathies.
 Stronger predictor of outcome than LVejection
fraction (EF) and LV volumes in chronic stable
disease (HF, chronic CAD)
 Stronger predictor of outcome than LV-EF and LV
volumes in acute myocardial infarction
 Stronger predictor of malignant ventricular
arrhythmia, sudden death and lower likelihood of
improvement with medical therapy in various
patient groups with cardiomyopathy
 LGE transmurality able to inform on reversibility of
underlying regional wall motion abnormality
 MVO and IMH - predictors of poor outcome, but
uncertainty whether these are independent [61] of
infarct size or interrelated [62] (IMH occurs in a
subset of MVO)
Development directions
 Standardization of acquisition methods and nulling
approaches to achieve similar relative signal-to-noise
ratios of fibrotic tissue versus normal myocardium
(currently dependent on contrast agent type, dose and
time after injection, field strength, type of sequence and
other variables including the underlying injury itself).
 Improved definition of transmurality and segmental
allocation for visual interpretation
 Standardization of quantification methods for LGE.
Studies used the FWHM and the SD-based
methods, however, this remains suboptimally stan-
dardized in terms of
○ To determine the cut-off value, the method with
the best prognostic/ diagnostic value.
○ The different data acquisition techniques and
post-processing algorithms may require different
post-processing approaches.
ii. T2 weighted imaging
Myocardial tissue characterization using electrocardio-
gram (ECG)-triggered T2 weighted (T2W) sequences is
used to demonstrate the regional differences in myocar-
dial water content. T2W imaging is optimally suited to
visualize regional oedema, such as in acute myocardial
infarction, supporting assessment of area at risk (AAR)/
myocardial salvage index (MSI). It was also applied in
myocarditis imaging, as a part of Lake-Louise Criteria
(LLC). Owing to lengthy and artefact-prone acquisitions,
T2W imaging is less fit for use in everyday clinical prac-
tice, and increasingly replaced by the modern quantifi-
able acquisition alternatives, T1 and T2-mapping.
Acquisition
Several sequences/approaches are available for T2W car-
diac imaging [1]:
○ T2W black-blood turbo spin echo (T2W-TSE)
○ T2W short tau inversion recovery (STIR),
○ T2-prepared SSFP
○ Emerging new approach for AAR using contrast-
enhanced SSFP (based on T2 and T1 contrast) for
AAR assessment based on the acquisition of the cine
LV stack [63]
 Technical limitations of T2W CMR pulse sequences
are susceptible to various influences causing some
limitations as endpoints and in clinical practice:
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○ long acquisition time over 2 heart beats result in
long breath-holds and artefacts due to cardiore-
spiratory motion;
○ variations in phase array coil sensitivity
○ high signal from slow moving blood (e.g. at the
subendocardium and in the ventricular apex)
○ low contrast-noise ratio in differentiating
oedematous vs. normal tissue
Post-processing
 T2W imaging of AAR/myocardial salvage
((Additional file 4: Tables 3b-ii.1–2):
○ Myocardial salvage is calculated by subtraction
of percent infarct size (by LGE) from percent
AAR (by T2W imaging) [64, 65].
○ MSI is calculated by dividing the salvage area by
the AAR.
○ Post processing is subjective (based on ‘n’-SD
threshold approaches or visual delineation)
○ Optimal imaging time for AAR assessment is
ideally 4–7 days after acute MI [62].
 T2W imaging in myocarditis (LLC) [66]:
○ Visually determined areas of hyperintensity in
T2W images
○ Global oedema ratio: semi-quantitative analysis
by normalizing the signal intensity of the myocar-
dium to that of skeletal muscle: values of more
than 1.9 indicate myocarditis
Validation
 Hyperintense signal on T2W CMR has been shown to
indicate increased myocardial water content, whereas
hypointense signal within the hyperintense injured
zone indicates IMH (Additional file 4: Table 3b-ii.1)
 Phantom and Tissue studies
○ Proton transverse (T2) relaxation times reflect
tissue hydration.
○ Alterations in T2 signal enable visualisation of
regional myocardial oedema as area of
hyperintense signal
 Animal models
○ The ischemic AAR consists of oedema and is
typically greater than infarct size - > T2W
imaging represents a non-invasive approach to
AAR estimation.
○ T2W imaging enables retrospective
determination of the ischaemic area-at-risk
○ Comparison of contrast-enhanced bSSFP with
myocardial perfusion SPECT
 Human studies
○ Dynamic changes of AAR after acute myocardial
infarction [65, 67, 68]
○ Comparison of T2W AAR by CMR with
myocardial perfusion SPECT
○ Comparison of contrast enhanced bSSFP with
myocardial perfusion SPECT [63]
○ LLC vs. EMB-criteria for myocarditis
(Additional file 4: Table 3b-ii.1)
Precision
 Available data on reproducibility of T2W imaging
for AAR [69, 70]
 Comparison of T2W vs. T2 mapping for AAR
reveals T2 mapping to be more reproducible [71];
 Comparison of seven post-processing approaches
for quantifying oedema in T2W imaging in
acute MI (2 SD, 3 SD, 5 SD, Otsu, FWHM,
manual threshold, and manual contouring)
revealed that manual contouring provided the
lowest inter, intraobserver, and interstudy
variability for both infarct size and oedema
quantification [72].
 The FWHM method for infarct size quantification
and the Otsu method for myocardial oedema
quantification are acceptable alternatives [72].
 No data available for contrast-enhanced bSSFP
 No data available for oedema ratio in myocarditis
Normal values
 Normal reference = absence of hyperintense signal
(poor negative predictive value)
 In myocarditis: semiquantitative ‘oedema ratio’ of
< 1.9 (SI of myocardium/SI of skeletal muscle) [66]
Qualification and utilization
○ Detection of myocardial damage in patients with
acute coronary syndrome (ACS) [73]
○ Determination of salvaged myocardium in STEMI
patients, prediction of higher revascularisation rate and
adverse prognosis (Additional file 4: Table 3b-ii.4).
○ Randomised controlled trials using T2W and
contrast-enhanced bSSFP AAR as an endpoint
(ischaemic preconditioning [74, 75].
○ T2-oedema ratio variable sensitivity across
inflammatory cardiomyopathies with moderate
positive and poor negative predictive value
(Additional file 4: Table 3b-ii.3)
○ No prognostic or therapeutic studies
Development directions
 Native T2 mapping methods enable quantification of
T2 relaxation times and are less susceptible to
artefacts (see chapter on T2 mapping)
 The utility of T2W-imaging in excluding ACS in the
emergency room has become less prominent since
the advent of high-sensitivity troponin assays.
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6. Quantitative tissue characterisation
i. T1 mapping
T1 mapping is a quantitative tissue characterization
technique, which allows quantifying the rate of longitu-
dinal relaxation of myocardial tissue (and blood). The
resulting measurements come as an absolute number
(time, ms), which is sequence-specific, requiring
standardization of acquisition and calibration of values
in health and disease.
Acquisition
Sequences allowing acquisition of a series of images
(using increasing time delays) during the evolution of
the longitudinal relaxation:
 Acquisition in mid-diastole (owing to a lengthy
image acquisition time, systolic acquisition window
less robust)
 Magnetisation preparation by inversion (180°) or
saturation (90°) prepulses
 Several imaging schemes with differences in
number of images, pauses for magnetization
recovery (which can be defined as either
beats or seconds), flip angles, use of
adiabatic prepulses, acceleration techniques
(half-scan, partial Fourier)
○ resulting in differences in T1 accuracy
(with consequences for precision and diagnostic
accuracy, see below).
 Native (without GBCA) and post-contrast
T1 mapping (typically ~ 10–15 min after
administration of GBCA, dose and type of GBCA
not standardized)
 Single (midventricular) short axis slice (− > diffuse
myocardial disease) or three short axis slices (apical,
midventricular, basal) (− > regional myocardial
disease)
 Heart-rate dependency:
○ for myocardial T1 with most sequences
not relevant within physiological heart rates
< 80 bpm;
○ less important for post-contrast images,
more relevant for long T1 values such
as native blood, or in very severe
myocardial disease (amyloidosis, severe
oedema), as more time needed for full
relaxation;
○ every other beat acquisition (2RR intervals) may
be used in tachycardia
 Extracellular volume fraction (ECV) calculation
based on pre- and postcontrast T1 mapping
acquisitions and blood values which requires
standardization and heart rate correction
for each component (unclear: identical
sequences/ different schemes for
pre/postcontrast acquisitions)
Post-processing
 Pixel-wise image reconstruction and exponential
curve-fitting of signal intensity values (3-parameter
fitting model):
○ magnitude image detection: SMAG(t) = abs
(A – B exp.(−t/T1*)
○ phase sensitive inversion recovery
(PSIR) detection : SPSIR(t) =
A – B exp.(−t/T1*).
 T1 value equates with the time at 63% recovery of
longitudinal magnetisation
 Post-processing affected by the regional variation
due to variable sensitivity of phase array coils
and artefacts in the lateral wall (septal region
of interest (ROI) more precise compared to
SAX ROI, segmental values difficult to normalise)
 Myocardial ROI placement:
○ diffuse (global) myocardial involvement:
▪ septal ROI [76] or SAX ROI [77, 78]
▪ excluding areas of LGE
▪ conservatively within the myocardium [76]
○ regional myocardial T1 values:
▪ Segmental ROI placement [79]:
▪ Significant regional differences in T1
values - > difficulty in normalising segmental
T1 values
▪ No significant differences between septal
values for basal and midventricular slice,
however considerable overestimation in apical
slice (due to partial volume)
 Blood ROI placed in the centre of the blood pool
using same acquisition as above, avoiding papillary
muscles
 Post-contrast T1 blood: less in-flow effect compared
to native T1
 T1 indices (Additional file 3: Table 3c-i.1):
○ direct measurements: native T1, post-contrast T1
○ calculated indices based on pre- and post-
contrast T1 mapping acquisitions:
▪ lambda (partition coefficient of contrast agent
distribution between blood and myocardium)
= (R1myocardiumnative-R1myocardiumpost-
contrast)/ (R1bloodnative- R1bloodpost-
contrast), where R1 = 1/T1
▪ ECV is partition coefficient lambda, which
relates to the extracellular space only, by
accounting for intracellular space of blood by
haematocrit (requires contemporaneous blood
sampling): =(1-Ht)x lambda
▪ synthetic ECV calculation
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• derived from a relationship between
haematocrit and longitudinal relaxation rate
of blood (R2 = 0.51)
• derived for selected sequences and a single
vendor only [80, 81]
Validation
 Phantom sequence characterisation (T1 accuracy
and precision)
 Histological correlation with collagen volume
fraction (Additional file 3: Table 3c-i.2)
○ Correlations vary between reports
○ Differences in staining techniques, inclusion/
exclusion of areas of LGE
○ Differences in sequence parameters, type/dose/
timing of GBCA, different sequences used in
pre/postcontrast acquisitions, post-processing
(ROI placement)
 Several components of the measured values do not
occur in phantoms, such as magnetisation transfer,
water-exchange, T2 sensitivity, inflow effects, making
a full validation in phantoms or ex-vivo impossible
Precision
 Evidence on interstudy, inter- and intraobserver
variability (Additional file 3: Table 3c-i.3)
 No benchmarking datasets available as variability
seems mainly dependent on data acquisition
Normal values
 Some sequences have established normal values
(Additional file 3: Table 3c-i.4). Of note, every
specific implementation may yield slightly different
values and requires standardization.
Qualification and utilisation
Abnormal (raised) myocardial T1 values indicate the
presence of diseased myocardium and relate to worse
outcome:
 Disease models: myocarditis, non-ischaemic dilated
cardiomyopathy, amyloidosis, ischaemic cardiomy-
opathy, hypertrophic cardiomyopathy (Additional
file 3: Table 3c-i.5)
 Outcome data (Additional file 3: Table 3c-i.6): T1
values are stronger predictor of outcome than LV
function, volumes and LGE:
○ Amyloidosis
○ Non-ischaemic dilated cardiomyopathy
○ Mixed patient cohorts
Development directions
 Sequence and vendor specific standardization of
acquisition, normal values and calibration of values
in health and disease
 Outcome data
 Data on guiding management
 Pre- and post-contrast T1 mapping acquisitions
○ unclear whether identical sequences or
different schemes for pre/post-contrast
acquisitions amount to a justifiable
counterpart of pre/post-contrast acquisition,
but rather a mix of poorly related diagnostic
tests.
ii. T2 mapping
T2 mapping is a quantitative tissue characterization
method mainly reflecting the water content of the myo-
cardium. It is based on a series of images with different
time delays acquired during the diastolic standstill to
map the T2 magnetization decay. Increasing evidence
base for T2 mapping supports its utility in detection of
myocardial inflammation and oedema, in myocarditis
and in assessment of acute myocardial infarction (AMI).
Myocardial T2 values were shown to decrease with
anti-inflammatory treatment.
Acquisition
 Sequences acquiring separate images during the
evolution of the transverse relaxation in diastolic
standstill
 T2 prepared spin echo sequences with several
different schemes with differences in number of
image acquisitions, flip angles, accelerating
techniques, single-shot vs. multiecho
○ T2-prepared bSSFP sequence
○ T2-hybrid gradient echo and spin echo (GraSE)
sequence
 Native acquisition (no contrast agent)
 Single (midventricular) short axis slice
(− > diffuse myocardial disease) or three
short axis slices (apical, midventricular, basal)
(− > regional myocardial disease)
 No regional variation due to variable sensitivity of
phase array coil
Post-processing
 Pixel-wise image reconstruction and exponential
curve fitting
 T2 value equates with the time at 63% decay of
transverse magnetisation, direct myocardial
measurement
 ROI placement:
○ Myocardial septal ROI or SAX ROI (in case of
diffuse myocardial disease)
○ Segmental ROI placement (in case regional T2
values are desired)
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 No significant difference in segmental values for
basal and midventricular slice, overestimation in
apical slice (partial volume)
Validation
 Phantom sequence characterisation (T2 accuracy
and precision)
 Histological validation (Additional file 5: Table 3c-ii.1).
 in animal models
○ AAR
○ AMI reperfused and non-reperfused
▪ Detection of AAR (comparison with
T2W/LGE approach as reference
standard)
 Model diseases: AMI, myocarditis, transplant
rejection
 Validation of water component difficult in animals
and biopsies
 Has been shown to be superior to T2W imaging
and Lake-Louise Criteria for the diagnosis
of acute myocarditis (Additional file 5:
Table 3c-ii.2)
Precision
 Interstudy, inter- and intraobserver variability
(Additional file 5: Table 3c-ii.3)
 No benchmarking datasets available as
variability seems mainly due to data
acquisition
Normal values
 Several sequences have established normal values
(Additional file 5: Table 3c-ii.4)
Qualification and utilisation
 T2 mapping useful in detecting myocardial
oedema and inflammation (Additional file 5:
Table 3c-ii.5)
○ Acute myocardial infarction
○ Myocarditis, inflammatory cardiomyopathies,
including cardiac involvement in systemic
inflammatory diseases, tako-tsubo
cardiomyopathy
○ Early detection of ongoing inflammation
with the possibility of reversal of
myocardial damage using
anti-inflammatory intervention may be
feasible.
○ Added value to T1 mapping in inflammatory
conditions, by informing on active inflammation
and reversal upon anti-inflammatory interven-
tion [82–84]
iii. T2* mapping
T2* mapping is a quantitative test for the assessment
of myocardial iron load in patients with thalassemia.
T2* mapping is also employed for visualisation of
IMH, such as during or after an acute ischaemic
event.
Acquisition
 As per SCMR protocols:
○ single breath-hold multiecho T2* gradient echo
sequences (black-blood prepulse) [1]
○ a single midventricular SAX slice - > septal
T2*measurement
○ 3 short axis slices - > global T2* measurement
 Each sequence yields sequence specific “absolute”
T2* values (in ms)
 Each sequence requires standardisation (validation,
normal values, clinically relevant cut-off values)
prior to clinical use
 Only 1.5 T and 3 T datasets are validated
for measurement of cardiac iron content
[85, 86];
Post-processing
 As per SCMR standardised image interpretation and
post-processing [2]
 T2* values = the time delay taken for decay of the
myocardial signal by 63%
 ROI placement:
○ Myocardial septal ROI in midventricular
slice encompassing both epicardial and
endocardial borders, to prevent the
epicardium-endocardium heterogeneity
of iron deposition (informs on global
myocardial iron content)
○ Segmental ROI placement (− > regional T2*
values)
○ Complete SAX coverage in basal,
midventricular and apical slice generates a
global T2* value, however, this is less
frequently used.
 Significant differences in segmental values
reported. Regional variation most likely due to
variable sensitivity of phase array coils to different
regions.
Validation
 Validation against myocardial and liver iron content
(Additional file 6: Table 3c-iii.1 and 2)
○ Ex vivo histological validation - > good
correlation of T2* measurements versus
chemically assayed iron
○ Biopsy not useful as reference standard
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○ Therapy guidance by T2* imaging is superior
to other tests – as such T2* in thalassemia
can be regarded as the clinical reference
standard
Precision
 Evidence on interscanner, intercenter, interstudy,
inter- and intraobserver variability (Additional file 6:
Table 3c-iii.3)
Normal values
 Iron loading:
○ Normal values for 1.5 T (Additional file 6:
Table 3c-iii.4)
○ Established clinically relevant cut-offs
of significant myocardial iron loading
(septal ROI):
▪ T2* < 20 ms: clinically relevant myocardial iron
loading
▪ T2* < 10 ms: severe myocardial iron loading
 IMH - intramyocardial hemorrhage
○ A myocardial region of interest with
a T2* < 20 ms is taken to represent
haemorrhage
○ T2* (< 20 ms) is highly discriminative of
haemorrhagic transformation within the infarct
zone vs. infarct zone without haemorrhage or
the remote zone
Qualification and utilisation
 T2* useful in detecting relevant cardiac iron
overload involvement in thalassemia major – > at
T2* < 20 msec
 In cardiac iron loading T2* correlates closely with
○ negative cardiac remodelling (ejection fraction,
end-diastolic volume (EDV)) and diastolic
dysfunction (Additional file 6: Table 3c-iii.2)
○ clinical events (HF, arrhythmia) and
○ response to iron-depletion treatment (Additional
file 6: Tables 3c-iii.5 and 6)
 Comparison with historical data indicate improve
survival of patients at risk of iron overload
due to cardiac T2* mapping guided iron-depletion
therapy [87]
 Interdisciplinary consensus statements recommend
surveillance of patients at risk of cardiac iron
overload using cardiac T2* mapping [88]
 Serial changes in myocardial oedema and
haemorrhage in ischaemic and remote zone after
reperfusion [62]
 IMH detection by T2* core is independently
associated with adverse LV remodelling, major
adverse cardiac events and mortality [89]
7. Stress myocardial perfusion with CMR
Myocardial perfusion CMR testing under the effect of
pharmacological agents (myocardial stress-perfusion) is
used to demonstrate regional reduction in myocardial
perfusion to assess the presence of hemodynamically
significant coronary artery stenosis. Myocardial stress
perfusion CMR imaging is a routinely used diagnostic test
in patients presenting with symptoms and signs of stable
angina. It is also used in patients with medium-to-high
pretest likelihood of significant (flow-limiting) coronary
artery disease (CAD), patients with known coronary
artery stenosis to assess significance of specific le-
sion(s) and patients with previous revascularization or
myocardial infarction. Myocardial stress perfusion
CMR imaging can also demonstrate the presence of
microvascular disease e.g. in patients with angina and
normal coronary arteries. In this case, the imaging ab-
normality during stress testing is typically hypoperfu-
sion of the sub-endocardium with a circumferential
distribution. Myocardial stress perfusion CMR im-
aging may be useful to demonstrate potential CAD
aetiology in patients with HF with or without reduced
LV ejection fraction. Quantitative perfusion imaging is
increasingly becoming available.
Acquisition
 Acquisition as per SCMR Standardized Protocols [1]
○ Dynamic acquisition during the passage
of the contrast agent bolus
(dose 0.05–0.1 mmol/kg body weight)
through the left ventricular cavity and
the myocardium;
○ First pass acquisition during pharmacological
stress;
○ Repeat pass acquisition at rest (may be omitted
for qualitative assessment, if LGE is available to
determine infarction)
○ 3 short axis slices (basal, midventricular and
apical) every heart beat for a minimum of 40–50
heart beats→ a minimum of 40–50 dynamic
measurements);
○ 3D whole heart acquisition methods available,
currently no demonstrated diagnostic advantage
over 2D 3-SAX slice acquisition [90];
 Sequences: various sequences available based on
saturation prepulse for preparation of magnetization
and acquisition of data with either:
○ spoiled fast gradient echo (GrE);
○ bSSFP pulse sequences;
○ typically combined with acceleration techniques:
▪ echo planar imaging (GrE-EPI);
▪ spatial undersampling (e.g. sensitivity encoding
(SENSE)
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▪ generalized autocalibrating partially parallel
acquisitions (GRAPPA),
▪ spatio-temporal undersampling (e.g. k-t Broad
Linear Speed up Technique, k-t BLAST or k-t
SENSE);
○ differing in the acquired spatial (3x3x8 mm to
1.3 × 1.3x8mm) resolution.
 Diagnostically relevant is the stress acquisition.
 The rest acquisition is used to:
○ discern possible artefacts
○ to support calculation of parameters based
on the change of stress and rest perfusion
(e.g. myocardial perfusion reserve
index - MPRI or myocardial blood flow –
MBF - reserve).
 Pharmacological stress is the standard
approach (adenosine, regadenosone, dobutamine);
exercise stress has shown feasibility in research
settings.
Post-processing/interpretation
 as per SCMR Standardized Postprocessing [2]
○ Visual interpretation is the standard clinical
approach:
○ Hypoperfusion is defined as segmentally reduced
contrast agent uptake at peak stress persisting
for 5 consecutive heart beats
▪ not present at rest,
▪ outside the enhanced myocardium on LGE
images.
○ several diagnostic standards of test positivity
proposed demonstrating a reduced increase of
flow or reduced peak flow in areas subtended by
vessels with significant coronary stenosis (see
below)
 The benefits of quantitative and semi-quantitative
over qualitative interpretation remain at present in-
vestigational. Quantitative and semi-quantitative
evaluation require:
○ stress and rest acquisition to calculate perfusion
reserve or perfusion reserve indices; peak
perfusion can be determined from stress images
only
○ dual bolus, dual contrast sequences or other
algorithms to correct for the non-linearity of
signal intensity and contrast agent at higher
doses
○ correction for baseline signal differences
○ efficient motion correction
○ a myocardial perfusion reserve index (MPRI)
can be calculated from various parameters,
usually using the relative upslope between rest
and stress (corrected for changes of upslope of
the contrast bolus in the left ventricle)
○ full quantification can be achieved with various
mathematical algorithms (e.g. Fermi deconvolution,
Patlak plot).
Validation
 Excellent validation of technique (Additional file 7:
Table 3d.1 and 2):
○ Flow in phantoms and microspheres in animals;
○ Comparative effectiveness diagnostic studies and
meta-analyses studies of CMR to PET, SPECT,
invasive coronary angiography and invasive flow
measurements (fractional flow reserve – FFR;
Additional file 7: Table 3d.1). Favorable results
in comparison to SPECT due to higher spatial
resolution. [91, 92]
○ Outcome studies of stress myocardial perfusion
CMR imaging validating predictive association of
positive and negative outcome (Additional file 7:
Table 3d.3), similar results to SPECT.
○ Quantitative perfusion imaging: many
approaches require more validation, especially as
large outcome studies have been performed with
visual analysis
Precision
 Limited evidence on interstudy, inter- and
intraobserver reproducibility due to need of stress
and contrast injection (Additional file 7: Table 3d.2)
Normal values
 Limited data on normal values due to lack of
standardization of image acquisition and post-processing
 Visual assessment: several diagnostic standards on
the interpretation of the presence/severity/
prognostic relevance of myocardial hypoperfusion
based on number of affected segments:
○ ESC guidelines on stable CAD (16 segment
ACC/AHA segmentation) [93]:
▪ ≤2/16 segments indicate a good prognosis with
optimal medical therapy (OMT) (negative test)
▪ ≥ 3/16 segments defined as prognostically
relevant (warrants attempt to revascularize on
prognostic grounds (positive test)
○ Subsegmentation into 32 segments (with endo-
and epicardial division):
▪ ≤ 3/32 segments indicate a good prognosis
with OMT
▪ ≥4/32 segments defined as prognostically
relevant [94]
○ MR-INFORM: prognostically relevant ischaemia
[95]:
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▪ Either transmural hypoperfusion defect or
perfusion defect affecting 2 slices or > 60% in basal
and midventricular slice, > 90% in apical slice.
 (Semi-) quantitative assessment of MBF, MPR or
MPRI: experimental data available for different field
strengths
Qualification and utilisation
 Data from prospective observational studies using
stress myocardial perfusion CMR have shown
significant predictive association for the presence/
severity of myocardial ischemia with outcome
(Additional file 7: Table 3d.3):
○ Effective cardiac risk reclassification in patients
with known or suspected stable CAD [96].
○ Excellent negative predictive value - > low event
rate in patients with a negative test
○ Excellent positive predictive value substantiating
the role for revascularisation following positive
test to improve prognosis
○ Improvement of MPR after percutaneous
coronary intervention (PCI)
Development directions
 Standardization of post processing methods
(semi quantitative and quantitative) to allow
definition of normal values, effect sizes and
improvement of reproducibility. Different post
processing methods may apply for different data
acquisition techniques.
 Improvement of spatial resolution / coverage based
on faster acquisition techniques (e.g. compressed
sensing)
 Quantitative perfusion imaging is increasingly
becoming available. At this stage the various
approaches require more validation, especially as
large outcome studies have been performed with
visual analysis.
8. Vascular endpoints
CMR allows a comprehensive assessment structure and
function of the great vessels by anatomical assessment of
vessels dimensions and cross-sectional areas, functional
assessment of the vessel wall (aortic strain and distensibil-
ity, and central (aortic) pulse wave velocity (PWV)). Tissue
characterisation by T1-, T2- and proton density-weighted
imaging and, more recently, by T2 mapping allows
characterization of tissue composition.
Acquisition
Acquisition as per SCMR standardised protocols
 Anatomy and dimensions:
○ cardiac triggered-contrast enhanced CMR
angiography
○ free-breathing 3D balanced acquisition.
 Wall thickness and wall volume by black blood
CMR
 Distensibility and strain: balanced (cine) image
acquisitions orthogonal to the vessel of interest;
 PWV: measurement of pulse wave travel time/path
between ascending and descending aorta
○ ‘through plane’ flow acquisitions in ascending or
descending aorta and an anatomical image of
thoracic aorta.
○ ‘inplane’ velocity acquisition of thoracic aortic
candy-cane
 Wall tissue characterisation by:
○ T2 weighted sequences
○ T1 inversion recovery GRE sequences (vessel
wall gadolinium enhancement)
Post-processing
 Inner-vessel diameters, cross-sectional areas
 PWV: travelled path divided by time delay.
○ Foot-to-foot
○ Upslope measurements
 Tissue characterisation
○ Visual assessment
○ Contrast-to-noise (CNR) measurements
Validation
 Comparative studies for aortic PWV and
distensibility with alternative techniques, including
invasive and tonometric PWV measurements
(Additional file 8: Table 3e.1)
 T2 mapping vs. histology of carotid specimens
showing accurate quantification of plaque lipid
content and the different plaque composition
despite similar grade of stenosis (Additional file 8:
Table 3e.1).
Precision
 Limited evidence on interstudy reproducibility of
anatomical and tissue measurements
 Excellent evidence for PWV: measurements highly
reproducible
Normal values
 CMR data from large healthy populations are
available for different anatomical and functional
measurements adjusted by age, sex and body mass
index (BMI) (Additional file 8: Table 3e2).
Qualification and utilisation
 Guiding management in aortic dilatation and aortic
valve replacement (Additional file 8: Table 3e2)
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 Aortic wall imaging and PWV serve robust
biomarkers of cardiovascular risk
Development directions
 Functional assessment of reactive ischemia (or oximetry
after cuff induced limb ischaemia) or exercise-induced
blood flow in peripheral artery disease [97, 98]
Conclusion
Not applicable.
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